This Week's Lows
| Ticker | Company | Business | Price | Mkt Cap | From High | 1M | 3M | Why It's Here | Index |
|---|---|---|---|---|---|---|---|---|---|
| LFT | Lument Finance Trust | Mortgage REIT | $1.16 | 61M | -57% | -9% | -11% | Commercial real estate credit stress rising; loan book markdowns and dividend sustainability concerns mounting. | |
| SNT | Senstar Technologies | Security tech | $2.75 | 64M | -49% | -5% | -26% | Physical security budgets cut as enterprises prioritise cybersecurity spend; Middle East contract pipeline delayed. | |
| BEEP | Mobile Infrastructure Corp | Parking asset operator | $1.88 | 77M | -60% | -16% | -40% | Rising vacancy rates in urban parking; remote work reducing weekday parking demand structurally. | |
| SPWR | SunPower Inc | Solar energy | $1.04 | 131M | -54% | -13% | -32% | Residential solar demand collapsed as high interest rates made financing unaffordable; Chapter 11 restructuring recently completed. | |
| SNWV | SANUWAVE Health | Medical devices | $15.64 | 134M | -66% | -9% | -39% | Wound care reimbursement cuts reducing hospital adoption; shockwave therapy device uptake slower than projected. | |
| STEX | Streamex Corp | Tokenized commodities | $1.01 | 183M | -93% | -11% | -66% | Gold-related tokenized asset volumes collapsed; business model viability questioned with minimal operating revenue. | |
| GWRS | Global Water Resources | Water utility | $7.06 | 203M | -37% | -8% | -20% | Regulatory rate case delays limiting revenue growth; Arizona drought conditions straining infrastructure costs. | |
| SENS | Senseonics Holdings | Medical devices | $5.01 | 209M | -67% | -25% | -27% | FDA approval delay for next-generation implantable glucose sensor; cash burn accelerating with no clear near-term commercialisation. | |
| WNC | Wabash National | Truck trailers | $7.60 | 309M | -41% | -11% | -31% | Freight recession deepening; trailer order backlog evaporating as trucking companies defer fleet replacement indefinitely. | |
| MSC | Studio City International | Casino resort | $2.60 | 501M | -61% | -9% | -14% | Macau gaming recovery stalling; VIP segment weak as China capital outflow restrictions tighten. | |
| ETD | Ethan Allen Interiors | Furniture retail | $20.04 | 510M | -36% | -8% | -16% | Housing market weakness reducing furniture demand; tariffs on imported goods compressing already thin margins. | |
| EVER | EverQuote Inc | Insurance marketplace | $14.61 | 517M | -49% | -5% | -15% | Auto insurance carrier ad spending pullback reducing platform revenue; customer acquisition costs rising sharply. | |
| ALT | Altimmune Inc | Biotech therapeutics | $3.02 | 586M | -61% | -9% | -39% | Phase 2 obesity drug results disappointed investors; broader biotech selloff compounding the decline. | |
| DGICA | Donegal Group | Property insurance | $16.32 | 617M | -23% | -5% | -15% | Elevated catastrophe losses in mid-Atlantic markets; combined ratio deteriorating amid competitive pricing pressure. | |
| TRUP | Trupanion Inc | Pet insurance | $26.36 | 1.1B | -54% | 2% | -21% | Veterinary cost inflation outpacing premium increases; loss ratio deteriorating as the company is forced to re-price coverage. | |
| NOMD | Nomad Foods | Frozen foods | $9.46 | 1.3B | -53% | -4% | -26% | FY2025 revenue fell 2.2% and earnings dropped 40%; Deutsche Bank downgraded to Hold with 2026 guidance implying further declines. | |
| MZTI | Marzetti Co | Specialty food | $116.22 | 3.4B | -39% | -19% | -25% | Private label competition intensifying in dressings and dips; input cost inflation squeezing margins on core categories. | |
| MMSI | Merit Medical Systems | Medical devices | $62.01 | 3.7B | -38% | -9% | -22% | Hospital capex budgets tightening; cardiovascular device pricing under payer pressure across key product lines. | |
| OLLI | Ollies Bargain Outlet | Discount retail | $82.45 | 5B | -42% | -15% | -23% | Closeout merchandise supply tightening; comparable sales growth decelerating as post-pandemic bargain shopping tailwinds fade. | |
| MKTX | MarketAxess Holdings | Bond trading platform | $154.89 | 5.4B | -33% | -12% | -5% | Argus downgraded to Hold citing heavy commission reliance vs recurring revenue; fixed-income trading market facing competitive pressure with Q1 revenue miss. | |
| DLB | Dolby Laboratories | Audio tech licensing | $58.41 | 5.6B | -25% | -5% | -9% | Smartphone unit volume decline reducing licensing fees; streaming royalty renegotiations compressing margins. | |
| KNSL | Kinsale Capital Group | Specialty insurance | $304.16 | 7B | -41% | -12% | -26% | Excess and surplus lines market softening as mainstream carriers return; combined ratio guidance raised amid competitive pricing. | |
| RYAN | Ryan Specialty Holdings | Wholesale insurance broker | $29.66 | 7.8B | -59% | -13% | -37% | Specialty insurance market softening; acquisition-driven growth model questioned as integration costs rise and market conditions ease. | |
| FSV | FirstService Corp | Property services | $128.01 | 8B | -39% | -9% | -19% | Commercial real estate transaction volumes down sharply; property management margins squeezed by rising labour costs. | |
| BLDR | Builders FirstSource | Building materials supply | $73.75 | 8.2B | -51% | -10% | -39% | Q1 2026 EPS of $0.27 missed estimates of $0.39 by 31%; revenue down 10% YoY as housing starts decline and management cut full-year margin guidance. | S&P |
| CLX | Clorox Co | Household products | $86.48 | 10.5B | -38% | -18% | -26% | FY2026 sales guidance cut to -6%; GOJO acquisition causing dilution and Goldman, UBS, Morgan Stanley all cut price targets after the earnings report. | S&P |
| ERIE | Erie Indemnity Co | Insurance services | $210.65 | 11B | -45% | -17% | -26% | Competitive pressures challenging customer retention and premium growth; auto and homeowners loss ratios under pressure from weather events. | S&P |
| PNR | Pentair PLC | Water solutions | $77.08 | 12.5B | -32% | -11% | -19% | Industrial water treatment capex slowing; residential pool equipment demand down sharply on housing market weakness. | S&P |
| LULU | Lululemon Athletica | Athletic apparel | $128.98 | 14.9B | -62% | -17% | -24% | Founder Chip Wilson advising rival brands Alo and Vuori; North America comps negative, stock hit lowest level since March 2020, down 30% in 2026. | S&PNDX |
| NVR | NVR Inc | Homebuilder | $5,932.12 | 16.2B | -31% | -12% | -26% | Mortgage rates staying elevated; new order pace slowing as affordability remains stretched for first-time buyers. | S&P |
| TSCO | Tractor Supply Co | Farm retail | $32.31 | 17B | -50% | -29% | -41% | Q1 2026 EPS of $0.31 missed estimates; flat same-store sales and weak companion animal category led Telsey to cut price target to $52 and 18 analysts to revise earnings downward. | S&PNDX |
| HCM | HUTCHMED China | Oncology biotech | $13.22 | 18.1B | -32% | -14% | -9% | China drug pricing reform cuts reimbursement rates; regulatory approval timelines extended across key oncology pipeline. | |
| BRO | Brown & Brown Inc | Insurance brokerage | $57.64 | 19.5B | -49% | -13% | -21% | Hard insurance market cycle moderating; premium rate growth slowing and organic growth guidance cut as competition returns. | S&P |
| CTSH | Cognizant Technology Solutions | IT consulting | $51.86 | 24.6B | -40% | -17% | -33% | JPMorgan cut price target from $92 to $74; cautious IT spending environment pressuring guidance despite Q1 EPS beat and 5.8% revenue growth. | S&PNDX |
| RMD | ResMed Inc | Sleep apnea devices | $209.43 | 30.5B | -29% | -7% | -22% | GLP-1 weight loss drugs raising long-term CPAP demand questions; competitive pressure from Philips recall recovery adding uncertainty. | S&P |
| RBLX | Roblox Corp | Gaming platform | $47.57 | 34.1B | -68% | -17% | -21% | Daily active user growth decelerating; monetisation per user declining as core teen demographic ages out of platform. | |
| SYK | Stryker Corp | Medical technology | $290.88 | 111.4B | -28% | -12% | -20% | Iran-linked cyberattack (Handala group) shut down global manufacturing for three weeks in Q1; revenue missed by 5% and EPS missed by 13%, though full-year guidance maintained. | S&P |
| DHR | Danaher Corp | Life sciences tools | $174.04 | 123.2B | -28% | -9% | -19% | Revenue of $5.95B slightly missed estimates; Morgan Stanley cut target to $255. Life sciences instruments declined as North American academic research spending weakened. | S&P |
| ABT | Abbott Laboratories | Diversified healthcare | $87.54 | 152.5B | -37% | -14% | -20% | Tariff exposure on imported medical components weighing on margins; diagnostics recovery slower than expected. | S&P |